UNITED ORTHOPEDIC reported revenue of NT$485 million in March, marking a year-on-year increase of 22.02% and setting a new monthly record. First-quarter revenue reached NT$1.297 billion, up 21.70% from the same period last year, making it the highest Q1 performance in company history and the second-highest quarterly revenue overall, closely trailing the record set in Q4 last year.
The company stated that the United States is the world’s largest market for orthopedic joint implants. Years of market cultivation have yielded results, with recent years showing consistent double-digit growth in revenue and a rising share of total sales. However, frequent changes in U.S. tariff policies remain a concern, as the final tariff rates—regardless of the outcome—are expected to impact gross margins for sales in the U.S. market.
Given the high gross margin in the U.S. due to the significant difference between product costs and selling prices, UNITED ORTHOPEDIC plans to manage the potential impact through revenue growth and expense control to keep effects within a manageable range.
With rapid growth in both the European and American markets, the company has achieved record-high annual revenues for four consecutive years. In Q1, the Asia-Pacific (APAC) region accounted for 40% of total revenue, followed by Europe, the Middle East, and Africa (EMEA) at 39%, and the Americas at 21%.
Specifically, revenue from the EMEA region increased by 34% in Q1, with its share rising from 36% in the same period last year to 39%. France remains the largest market in EMEA, and the company is actively expanding into other countries within the region to maintain its growth momentum.
In the APAC region, aside from Taiwan, Japan stands out as a super-aged society and a key target market. UNITED ORTHOPEDIC has already partnered with local distributors in Japan and expects significant revenue contributions this year.
Additionally, several products are expected to receive FDA approval for the U.S. market in 2024, including the Modular Revision Hip and Press-Fit Patellar Knee implants. These developments are expected to further strengthen the company’s foothold in the U.S. and drive overall performance for the group.
Resource: 聯合骨材3月、Q1營收年增逾2成 齊創新高
